Kornimate/medical-research-clean huggingface dataset:
emotions in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: through this study, a group composed of multiple sclerosis patients will be compared to a healthy volunteers group to determine if the positive emotions recognitions is preserved in the first group.

different studies have highlighted the specific deficiency concerning emotions recognition in multiple sclerosis. patients with multiple sclerosis are reported to have more difficulty recognising negative emotions, especially anger and fear. in this context, recode study has a twofold objective: * to determine whether the positive emotions recognition remains preserved by combining behavioural and neurophysiological measures (electrodermal activity). * to study this disorder's etiology through a comparison between a multiple sclerosis patient group and a control group (matched in sex, age, and education's level).

Eligibility criteria:
inclusion criteria: * male or female between 18 and 55 years old. * understand and able to express themselves in french. * experimental group : * relapsing-remitting form (rrms) * with an edss \< 4 (expanded disability status scale) * no significant motor, cerebellar or somatosensory disorders of the upper limbs or visual disorders (edss specific parameter \<2) * no flare-up in the last 6 weeks * no corticosteroids taken in the last 4 weeks * control group : * lack of global cognitive deterioration (according to brief international cognitive assessment for multiple sclerosis (bicams) standards). * gender, age and education level matching to the multiple sclerosis patients * understanding and signing the informed consent and information letter regarding participation in the study. * benefiting from health insurance coverage. exclusion criteria: * persons with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, perceptive or dysarthric disorders preventing verbal communication or reading, * people with sensory disorders (visual and auditory) that interfere with the performance of neuropsychological tests; * treatment with psychotropic drugs (except benzodiazepines and hypnotics). * refusal to participate after clear and fair information about the study. * major persons under guardianship, under judicial protection, persons deprived of liberty. * pregnant or breastfeeding women

Keywords: multiple sclerosis emotions recognition cognitive disorders
medication adherence therapy for opioid abusing pain patients

Conditions: Pain; Chronic Disease; Prescription Opioid Abuse

Summary: the purpose of this study is to develop and pilot test a combined behavioral and pharmacological intervention designed to decrease pain, functional interference, and drug abuse while increasing medication adherence.

project pain is a stage i behavioral therapies development project aimed at developing and pilot testing a novel intervention for patients with chronic non-malignant pain who have experienced difficulty managing prescribed opioids. the goals of the study are to: (1) develop the intervention and training materials; (2) develop therapist adherence and competence scales; (3) train therapists to deliver the intervention per the treatment protocol; and (4) pilot the intervention to assess its feasibility, acceptability and promise. the goals of the intervention are to: (1) improve adherence to prescribed opioids; (2) decrease the severity of patients' pain; and (3) improve patients' functioning and quality of life .

Eligibility criteria:
inclusion criteria: * uninterrupted pain of at least 6 months duration * pain is continuous, rather than intermittent * pain in the severe range (vas = 7-10) while medicated * poor response to non-pharmacological interventions for pain (if appropriate) * one or more of the following pain diagnoses: (a) back/neck pain; (b) myofacial pain; (c) neuropathic pain (e.g., diabetic or aids neuropathy, complex regional pain syndrome); (d) arthritic pain; (e) ms; or (f) sickle cell (must meet chronicity criteria) * evidence of tolerance/physiological dependence on opioid analgesics * current opioid use disorder (dsm-iv criteria) * continuous use of opioid analgesics for a minimum of 6 months prior to referral. \[note: this is consistent with minimum 6-month requirement for diagnosis of chronic pain\]. * minimum of 2 signs/symptoms of medication mismanagement identified by the referring md (problems with pain meds checklist) exclusion criteria: * please contact site regarding exclusion criteria for this study.
vertical augmentation using onlay versus inlay autogenous graft with simultaneous implant placement.

Conditions: Bone Resorption

Summary: using autogenous chin block for vertical augmentation with simultaneous implant placement at anterior maxilla region comparing between the onlay and inlay grafting techniques.

to study the vertical augmentation with simultaneous implant placement at anterior maxillary region. * p: patient requires implant at anterior maxillary ridge with vertical deficiency. * i:inlay sandwich technique with immediate implant placement. * c:onlay autogenous graft immediate implant placement. * o:outcome name measuring device measuring unit primary outcome: vertical bone gain cbct millimeter -secondary outcome(a): crestal bone loss cbct millimeter

Eligibility criteria:
inclusion criteria: * \* patients with partially edentulous anterior maxillary ridges. * patients were free from any systemic disease that interferes with bone healing. * absence of local pathosis at anterior maxillary area. * no history of any grafting procedure at the designated edentulous ridge. the edentulous ridge vertical dimension was less than 10 mm measured from the alveolar crest to the nasal floor (i.e.ridge had vertical inadequacy) with normal horizontal alveolar dimension or patient with increased inter-arch space. exclusion criteria: * \* patient with fully dentulous maxilla. * pregnant females. * presence of bad habits (severe bruxism, clenching). * systemic diseases that may interfere with bone healing.e.g. uncontrolled diabetes.
prophylaxis versus on-demand therapy through economic report

Conditions: Hemophilia A

Summary: the project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with kogenate bayer in adolescents and adults with severe haemophilia a (fviii \< 1%). the observational period will cover at least 5 years per patient. the long-term secondary prophylaxis group will be compared versus on-demand treatment group by the assessment of orthopedic status progression and pharmacoeconomics evaluation.


Eligibility criteria:
inclusion criteria: * age ≥ 12 years and ≤ 55 years * severe haemophilia a (fviii \< 1%) * absence of inhibitors (bethesda titre \< 0.6 bu/ml) * previous treated patients (prior exposure days \> 200) * kogenate bayer administered 20-30 iu/kg -3 times a week, for the prophylaxis group * ≥ 6 joint bleeds requiring treatment with fviii concentrates in the previous 6 months before enrollment, for on-demand group * written informed consent exclusion criteria: * concomitant severe and chronic diseases or congenital skeletal malformation * unreliability of patient or likelihood of follow-up failure * presence of inhibitors or history of inhibitors (in the previous 2 years) * currently on immune tolerance treatment * hepatic cirrhosis or liver disease in rapid progression * aids * platelet count \< 75,000/mm3 * presence of conditions that influence negatively patient´s compliance * participation in another study
comparative efficacy of lipid based artificial tears vs aqueous based artificial tears in managing ede

Conditions: Evaporative Dry Eye

Summary: this randomized clinical trial aims to compare the efficacy of lipid-based (recuro) versus aqueous-based (softeal) artificial tears in managing evaporative dry eye (ede) over six weeks. conducted in a hospital or ophthalmology clinic, the study includes 60 participants (aged 18-55, both genders) diagnosed with ede.

participants are randomly assigned to receive either lipid-based or aqueous-based artificial tears, following a block randomization method (block size of 4) generated using research randomizer. the primary objectives are to assess symptom reduction and improvement in quality of life, measured by the ocular surface disease index (osdi) and the sande questionnaire. objective assessments include tear film stability, meibomian gland function, tear volume, and ocular surface health.

Eligibility criteria:
inclusion criteria: * adults (both genders) aged 18-55 years diagnosed with evaporative dry eye (ede). * willingness to adhere to the prescribed treatment regimen (lipid-based or aqueous-based artificial tears). * include patients with a history of dry eye symptoms for at least 1-3 months. * ocular surface disease index (osdi) score ≥13, indicating the presence of mild to severe dry eye symptoms. * patients with tear break-up time (tbut) \<10 seconds, indicating tear film instability.(16) exclusion criteria: * use of any topical ophthalmic medications (e.g., lubricants, anti-inflammatory drugs, or cyclosporine) for dry eye within the last 1 month. * active ocular infection or inflammation (e.g., conjunctivitis, uveitis). * history of ocular surgery or trauma within the past 6 months. * participants currently wearing contact lenses or those who have worn contact lenses in the past three months. * systemic conditions known to impact ocular surface health, such as uncontrolled diabetes, autoimmune disorders, or sjögren's syndrome.
stress management modified cardiac rehabilitation in patients after acute myocardial infarction or heart failure

Conditions: Acute Myocardial Infarction; Heart Failure

Summary: the purposes of this study is to evaluate the improvement of a stress management involved cardiac rehabilitation program on the psychological states, quality of life and clinical outcomes of patients after acute myocardial infarction or heart failure.

the purposes of this study is to evaluate the improvement of a stress management involved cardiac rehabilitation program on the psychological states, quality of life and clinical outcomes of patients after acute myocardial infarction or heart failure. the investigators performed modified cardiac rehabilitation program involving stress management on the patients who suffered from acute myocardial infarction or severe heart failure who were admitted to the ccu. then the psychological states, quality of life and clinical outcomes were followed up.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 years old with a diagnosis of ami (include st segment elevated myocardial infarction and non-st segment elevated myocardial infarction) or heart failure exclusion criteria: * uncontrolled tachycardia (heart rate at rest \>120bpm * uncontrolled polypnea（breath rate at rest \>30 breath per minute * uncontrolled respiratory failure （spo2 ≤90%） * uncontrolled hypertension （pre-exercise sbp\>180mmhg or dbp\>110mmhg） * weight change in 72 hours \>1.8kg * uncontrolled hyperglycemia (random blood glucose\>18mmol/l) * uncontrolled malignant arrhythmia with hemodynamic instability * unoperated pseudoaneurysm、artery dissection * uncontrolled septic shock and septicopyemia * unoperated severe valvular heart disease or acute phase of heart failure caused by myocardial heart disease * nervous system disease, motor system diseases and rheumatic diseases considered possibly worsened by exercise * uncooperation of the patients
a study to investigate the safety and efficacy of kqb365 as monotherapy and in combination in participants with advanced solid malignancies

Conditions: KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer)

Summary: the goal of this clinical trial is to learn if kqb365 works to treat advanced solid tumor cancer in adults. it will also learn about the safety of kqb365. the main questions it aims to answer are: * what is the safe dose of kqb365 by itself or in combination with cetuximab? * does kqb365 alone or in combination with cetuximab decrease the size of the tumor? * what happens to kqb365 in the body? participants will: * receive kqb365 infusion weekly alone or in combination with cetuximab * visit the clinic about 9 times in the first 6 weeks, and then once every week after that.


Eligibility criteria:
inclusion criteria: * part 1 (monotherapy): histologically confirmed diagnosis of a solid tumor malignancy with either a kras g12c or kras g12s mutation. * part 1 (combo therapy) \& part 2: histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with either a kras g12c or kras g12s mutation. * unresectable or metastatic disease * no available treatment with curative intent * adequate organ function * measurable disease per recist v1.1 exclusion criteria: * active primary central nervous system tumors * cardiac abnormalities * active interstitial lung disease

Keywords: cetuximab kqb365
safety & efficacy of nuberol forte® in pain management

Conditions: Musculoskeletal Disorder; Pain Management

Summary: the global prevalence of musculoskeletal disorders (msd) ranges from 14% to as high as 42%. in addition who also estimates that 40% of people over the age of 60 years suffer from msd and about 80% of the people have had low back pain at some point in their life. in pakistan, to estimate the prevalence of msd, there is no data available based on the local population. locally, studies were conducted on the specific subject pools mainly considering the work related musculoskeletal disorders and backache. however, no real data is available for the symptomatic management of painful musculoskeletal disorders in multiple settings to calculate more generalizable results. so this study is planned and if we found good results then it will help physicians to prescribe the above said medicine to all such cases.

the management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventions. in order to provide optimal care to patients with musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive overview of the available evidence for the most effective treatment options for musculoskeletal pain presentations is essential. in this context, an observational study is planned on the efficacy and safety of analgesic combination (i.e nuberol forte®). nuberol forte® is a combination of muscle relaxant (orphanedrine) and an analgesic/antipyretic (paracetamol/acetaminophen). there are clear indications that the combination of orphenadrine with paracetamol may give increased antinociceptive activity and duration of action over and above the use of orphenadrine or paracetamol alone.

Eligibility criteria:
inclusion criteria: * patient with a clinical history of painful musculoskeletal disorder from last 1 year * patient aged ≥18 and ≤70 years inclusive of either sex * patient with ability to understand and sign written informed consent form. exclusion criteria: * known hypersensitivity to nuberol forte product, the metabolites, or formulation excipients. * patients with glaucoma, prostatic hypertrophy or obstruction at the bladder neck, myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction. * treated with nuberol forte to evaluate safety as per approved prescribing information for nuberol forte in pakistan. * pregnant (assesed on lmp) or breast feeding women (assessed on interview).

Keywords: musculoskeletal disorder, nuberol forte, pakistan
neonatal neurobehavioral and motor behavior in ultra early physical therapy intervention

Conditions: Neonatal Disease; Parenting; Premature Birth

Summary: investigation of the combination of neonatal neurobehaviourism and motor behavior in the assessment and ultra-early physical therapy intervention of premature neonates and parental support.

developments in neonatology and perinatal medicine in recent years have resulted in a remarkable development of the survival of premature infants. at the same time, several evaluation and intervention protocols have been developed, aiming at early diagnosis and intervention, but also and studies that are concluding and highlight the need for future well planed and in-depth research, mainly in areas related to early intervention. t. brazeltons' (1973) neonatal behavioural assessment scale (nbas) has been used in many studies of assessment and intervention in newborn-infant and their families and respectively h.r. prechtls' (1979) qualitative assessment of general movements (gms) in assessment studies, as a valid and reliable non-invasive procedure. however, the combination of their basic principles and guidelines has not been developed and tested in the context of ultra-early physiotherapy intervention in premature infants. the evaluation and strengthening of ultra-early physiotherapy intervention by combining basic principles of neonatal neuro-behavior (based on brazelton t.) and motor behavior (based on prechtl h.f.r.), in the context of individualized and developmental supportive care of premature neonates and infants and enhancing parental self-confidence. the research is based upon on three different researches: a) the cross-cultural adaptation of karitane parental confidence scale (kpcs) questionnaire. the sample will be parents of infants up to one year, b) the effect of ultra-early intervention on parental confidence of preterm infant parents. an experimental randomized controlled trial which will be conducted in the neonatal intensive care unit (nicu) until maternity hospital discharge. the sample will be premature infants and their parents and c) the effect of ultra-early intervention and parental confidence, on the development of premature infants up to the age of three months. an experimental randomized controlled trial which will be conducted in the neonatal intensive care unit (nicu) and upon their discharge from the maternity hospital up to the age of 3 months. the study sample will be premature infants and their parents.

Eligibility criteria:
inclusion criteria: * gestational age under 37 weeks * premature newborns hospitalised in the nicu for at least eight days * (for parents) be able to speak and read greek or english exclusion criteria: * newborns with congenital and chromosomal abnormalities. * newborns with severe accompanying pathological problems and congenital infections. * (for parents) with known history of drug or alcohol abuse or serious psychiatric disorders

Keywords: prematurity subsystem organization motor system state system general movements spontaneous mobility parental confidence neonatal neurobehavior
influenza vaccine in lung transplant patients - persistence of antibodies

Conditions: Influenza

Summary: this a sub-study of a 5-year study designed to investigate how antibody and t cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals. this study is designed to investigate influenza vaccine-induced antibodies in lung transplant patients between seasons.

in the recent past, immunization policy-making bodies advised against immunizing too early in the influenza season because vaccine-specific antibody may wane before the end of the influenza season. this recommendation was based on only a small amount of data in frail elderly individuals, and further examination of the evidence shows that influenza vaccine antibody may last much longer. the influenza immunization timing recommendation is now changed to immunize when vaccine is available and continue throughout the season. these changes led the investigators to the question of duration of influenza vaccine-induced antibody in lung transplant patients. no published studies of antibody persistence in this population could be found. as part of a 5-year study of influenza antibody response in lung transplant patients, in patients awaiting lung transplantation, and in healthy controls, serum was obtained before and 2-4 weeks after influenza immunization for each season. therefore, a serum sample was collected on each participant approximately 11 months after influenza vaccine administration for each of 4 years. to investigate duration of influenza antibody titers, antibody concentrations to the previous season's vaccine antigens were measured. the hypothesis is that immunosuppressed lung transplant patients would maintain protective concentrations of influenza antigen-specific antibodies (an antibody titer of at least 1:40) beyond the influenza season. \[this substudy that was originally registered to nct00205270 and subsequently registered to its own nct number for the purpose of clarity in linked results\]

Eligibility criteria:
inclusion criteria: * receiving care pre- or post-lung transplant at university of wisconsin hospital * healthy adult exclusion criteria: * allergy to eggs * moderate to severe febrile illness * active treatment for acute rejection * received season's influenza vaccine prior to enrollment

Keywords: pre or post-lung transplant healthy
relationship between "fodmaps" and "gvhd"

Conditions: Graft Versus Host Disease

Summary: with the stem cell transplanting increasing, patients which effected with "gvhd" were also increased. to evaluation the relationship between "fodmaps" and "gvhd", bone marrow transplant patients were recruited.

the feces were collected from the patients who had been successfully transplanted after bone marrow transplantation. after 24 hours of culture in the culture medium, the degradation rate of "fodmaps" was detected, and the relationship between the degradation rate and the occurrence time and degree of "gvhd" was observed

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of "aml","all","mds" or "mm" disease; 2. must be treated with bone marrow transplantation; 3. the transplanted bone marrow was successfully planted exclusion criteria: 1. gastrointestinal diseases； 2. age\>60; or age\<10； 3. probiotics or prebiotics were taken before enrollment